Literature DB >> 26469334

Correction: DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells.

Heidi Kontro, Giuseppe Cannino, Pierre Rustin, Eric Dufour, Heikki Kainulainen.   

Abstract

Entities:  

Year:  2015        PMID： 26469334      PMCID： PMC4607438          DOI： 10.1371/journal.pone.0141036

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


× No keyword cloud information.
There are errors in the “Oncomine data analysis” section of the Materials and Methods. It should read: Oncomine and CCLE data analysis We used the Oncomine Cancer Genomics Data Analysis tool [30] and Cancer Cell Line Encyclopedia, CCLE [35] to mine Usmg5 copy number profiles in a large subset of cancer cell lines [31, 34, 35, 38, 41, 65–69]. In the dataset, the log2 (≥ 0,34) values were analyzed. The number of DNA copies (= 2*(2^y-axis value)) were calculated as advised in Oncomine instructions. There are errors in the “Usmg5 copy number in cancers” section of the Results. It should read: Usmg5 copy number in cancer cell lines Since DAPIT over-expression induced EMT and glycolytic switch in HEK293T cells, we tested if DAPIT is over-presented in cancer cell lines. The Oncomine Cancer Genomics database and CCLE revealed a duplication (3–4 copies) of Usmg5 copy number in a large panel of cell lines (Table 2) Several datasets indicated uniform increase in copy number in various lung (NCI-H1775, NCI-H1993, NCI-H1563, NCI-H1755, VMRC-LCD, SBC-5, NCI-H1703), gastric (HCT116, Hs746T, MKN74, SNU-668), ovarian (OVTOKO, MCAS), liver (SNU-398) and pancreatic (PSN1, PANC-1) cancer cell lines. The copy number was also confirmed in breast (SUM-52PE), endometrial (AN3CA), esophagus (OE33), hematopoietic (MPLM6), kidney (SNU-1272) and lymphoid (Ki-JK) cell lines, being encountered once in the others. These data strongly suggest a role for DAPIT over-expression in cancers.
Table 2

Cancer cell lines expressing increased genomic Usmg5 copy number in Oncomine cancer genomics database and Cancer Cell Line Encyclopedia, CCLE.

ClassificationCancer typeCell lineDNA copy numberOncomine dataset/ CCLE
BoneOsteosarcoma143B2,76CCLE [31]
BrainBrain gioblastomaA-1723,48Berouchim brain [35]
Cerebral glioblastomaLN-182,78Berouchim brain [35]
BreastBreast adenocarcinomaMCF72,62Nicolsky Breast [32]
Breast carcinomaSUM-52PE3,603,42Nicolsky Breast [32]Chin breast2 [65]
CAL-513,28Hu CellLine2 [66]
MDA-MB-4682,96Hu CellLine2 [66]
CAL-1202,81Hu CellLine2 [66]
Hs 578T2,74Hu CellLine2 [66]
MDA-MB-3612,72Hu CellLine2 [66]
HCC18062,62CCLE [31]
Ductal breast carcinomaT-47D3,18Nicolsky Breast [32]
MFM-2232,85Nicolsky Breast [32]
Squamous cell breast carcinoma, Acantholytic variantHCC18062,88Hu CellLine2 [66]
Central nervous systemCannabinoid receptorCB12,69CCLE [31]
GliomaKSN602,59CCLE [31]
EndometriumEndometrial adenocarcinomaJHUEM22,60CCLE [31]
AN3CA2,602,59CCLE [31]Rothenberg CellLine [38]
EsophagusEesophageal adenocarcinomaJHESOAD12,61CCLE [31]
Barrett's adenocarcinomaOE332,772,65CCLE [31]Wooster CellLine [N/A]
GallbladderBiliary tract cancerSNU4783,49CCLE [31]
GastricCecum adenocarcinomaLS411N2,70Lu colorectal [67]
NCI-H4982,61Lu colorectal [67]
NCI-H7472,60Lu colorectal [67]
Colon adenocarcinomaSW6202,88Lu colorectal [67]
HCT-152,77Lu colorectal [67]
LS1802,72Lu colorectal [67]
Colon carcinomaHCT1162,942,782,782,77CCLE [31]Berouchim multicancer [34]Lu colorectal [67]Rothenberg CellLine [38]
Gastric cancerHs 746T3,542,90Rothenberg CellLine [38]Palanisamy gastric [N/A]
NCI-N873,41Palanisamy gastric [N/A]
KATO1113,34Palanisamy gastric [N/A]
YCC-163,21Palanisamy gastric [N/A]
HUG1N3,02CCLE [31]
YCC-93,00Palanisamy gastric [N/A]
YCC-62,85Palanisamy gastric [N/A]
SNU5202,69CCLE [31]
Gastric tubular adenocarcinomaMKN742,742,57CCLE [31]Rothenberg CellLine [38]
Gastrointestinal stromal tumorGIST 882X2,97Berouchim multicancer [34]
Signet ring cell gastric adenocarcinomaSNU-6682,932,80CCLE [31]Barretina CellLine 2 [31]
Hematopoietic tissueAcute Myeloid LeukemiaCMK1152,90CCLE [31]
KASUMI12,85CCLE [31]
CMK2,67CCLE [31]
M2-type of Myeloid LeukemiaKASUMI62,78CCLE [31]
Blast phase cronic myelogenous leukemiaMOLM62,782,60CCLE [31]Barretina CellLine 2 [31]
Chronic myeloid leukemiaBV1732,55CCLE [31]
LeukemiaNCO22,53CCLE [31]
ErythroleukemiaTF-12,60Barretina CellLine 2 [31]
KidneyClear cell renal carcinomaSNU-12723,132,77CCLE [31]Barretina CellLine 2 [31]
Renal carcinomaUOK1012,87CCLE [31]
Human proximal tubular cell line, immortalizedHK22,67CCLE [31]
Renal adenocarcinomaACHN2,55CCLE [31]
LiverHepatocellular adenocarcinomaSNU-3982,842,752,722,59CCLE [31]Rothenberg CellLine [38]Wooster CellLine [N/A]Barretina CellLine 2 [31]
Hepatocellular carcinomaLI73,40CCLE [31]
C3A2,62CCLE [31]
LungLung adenocarcinomaNCI-HI4353,15CCLE [31]
NCI-H17752,732,62CCLE [31]Lu lung [67]
NCI-H19932,792,722,62Lu lung [67]Sos CellLine [69]Wooster CellLine [N/A]
NCI-H15632,742,68CCLE [31]Lu lung [67]
NCI-H18382,63Lu lung [67]
NCI-H17552,862,58Sos CellLine [69]Rothenberg CellLine [38]
VMRC-LCD2,672,57CCLE [31]Rothenberg CellLine [38]
LU65A2,75Rothenberg CellLine [38]
Large cell lung carcinomaCalu-62,59Lu lung [67]
Giant cell lung carcinomaLU65B3,03Rothenberg CellLine [38]
Small cell lung carcinomaNCI-H5102,83CCLE [31]
DMS532,69Olejniczak CellLine 2 [68]
SBC-52,692,64CCLE [31]Rothenberg CellLine [38]
DMS1142,55CCLE [31]
Non-small cell lung carcinomaNCI-H15812,67CCLE [31]
Squamous cell lung carcinomaHCC18973,53CCLE [31]
NCI-HI7032,632,61CCLE [31]Wooster CellLine [N/A]
Lung carcinomaEPLC272H2,56CCLE [31]
Lymphoid tissueAnaplastic large cell lymphomaKi-JK3,212,80CCLE [31]Barretina CellLine 2 [31]
Non-Hodking B cell LymphomaJM12,79CCLE [31]
Non-Hodking T cell LymphomaSR7862,78CCLE [31]
SUDHL12,65CCLE [31]
Splenic marginal zone B-cell lymphomaSLVL2,63Rothenberg CellLine [38]
OvarianOvarian adenocarcinomaTOV21G2,98CCLE [31]
OVK182,89CCLE [31]
CAO V32,62CCLE [31]
Ovarian clear cell adenocarcinomaOVTOKO4,043,20CCLE [31]Barretina CellLine 2 [31]
Ovarian mucinous custadenocarcinomaMCAS3,052,922,68CCLE [31]Rothenberg CellLine [38]Barretina CellLine 2 [31]
Ovarian carcinomaOVSAHO2,72CCLE [31]
Ovarian carcinomaOVK122,65Barretina CellLine 2 [31]
Ovarian granulosa cell tumorCOV4342,80CCLE [31]
PancreasAmpulla of Vater adenocarcinomaSNU-4783,08Barretina CellLine 2 [31]
Pancreatic adenocarcinomaPSN12,752,61CCLE [31]Barretina CellLine 2 [31]
PANC12,642,53CCLE [31]Barretina CellLine2 [31]
PK12,53CCLE [31]
Panreatic carcinomaPK45H2,63CCLE [31]
YAPC2,62CCLE [31]
SkinCutaneous melanomaA72,81Wooster CellLine [N/A]
MelanomaIGR12,63CCLE [31]
Squamous cell adenocarcinomaHCC952,78Sos CellLine [69]
HCC-152,59Sos CellLine [69]
ThyroidFollicular thyroid carcinomaML12,53CCLE [31]

N/A indicating not available

N/A indicating not available There are errors in Table 2 and in its caption. Please see the corrected Table 2 and its correct caption below. There are errors in the last sentence in the penultimate paragraph of the Discussion. It should read: Interestingly, searching in the Oncomine cancer genomics database and Cancer Cell Line Encyclopedia, CCLE, revealed a duplication in Usmg5 copy number in various cancer cell lines (Table 2), highlighting several lung, gastric, ovarian, liver and pancreatic cancer cell lines by supporting fidelity in duplication. The copy number was also confirmed in some breast, endometrial, esophageal, hematopoietic, kidney and lymphoid cell lines. Despite the link between DAPIT and the tumorigenic capacity has not been sufficiently demonstrated, this result strengthens a correlative involvement of DAPIT in cancer and suggests a possible oncogenic function for it. There are errors in the References. Please view the correct additional references, which are also corrected in Table 3 and the article text described above. 65. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Throne NPet al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 2007;8(10):R215. doi: 10.1186/gb-2007-8-10-r215 66. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009 Apr;7(4):511–22. doi: 10.1158/1541-7786.MCR-08-0107 67. Lu X, Zhang K, Van Sant C, Coon J, Semizarov D. An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models. BMC Med Genomics. 2010 Jun 22;3:23. doi: 10.1186/1755-8794-3-23 68.Olejniczak ET, Van Sant C, Anderson MG, Wang G, Tahir SK, Sauter G et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res. 2007 Apr;5(4):331–9. Doi: 10.1158/1541-7786 69. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest. 2009; Jun;119(6):1727–40. doi: 10.1172/JCI37127
  1 in total

1.  DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells.

Authors:  Heidi Kontro; Giuseppe Cannino; Pierre Rustin; Eric Dufour; Heikki Kainulainen
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.